Facebook
X
LinkedIn
ForwardGastrointestinal Cancers 2027
This course offers Live (in-person) and Livestream (virtual) attendance options
Course Directors: Tanios S. Bekaii-Saab, M.D., Jeremy C. Jones, M.D., Harry H. Yoon, M.D.
April 2-3, 2027 - Ritz-Carlton - Rancho Mirage, California
Discover how emerging science is reshaping GI cancer care. Expert faculty will highlight breakthroughs in targeted therapy, immunotherapy, radiopharmaceuticals, molecular profiling, transplant strategies, and precision oncology across pancreatic, hepatobiliary, gastroesophageal, neuroendocrine, and colorectal cancers.
Expert faculty will examine innovative approaches to precision oncology, including next-generation radionuclide therapies for neuroendocrine tumors, the expanding role of RAS inhibition and molecularly targeted treatments in pancreatic cancer, and strategies for integrating biomarker-driven therapies earlier in the disease course. Participants will explore contemporary management of hepatocellular carcinoma, including transplant candidacy, downstaging approaches, perioperative treatment considerations, and the integration of systemic and locoregional therapies.
Additional sessions will address advances in biliary tract cancers, including FGFR2-targeted therapies and perioperative management, as well as emerging therapeutic targets in gastric and esophageal cancers such as HER2, CLDN18.2, and immunotherapy-based approaches. The activity will also highlight the growing clinical relevance of tumor spatial architecture, organ preservation strategies, measurable residual disease (MRD), and molecular characterization in treatment selection.
Target Audience
This course is designed for medical, radiation and surgical oncologists; gastroenterology surgeons, gastroenterologists and hepatologists involved in cancer care; interventional radiologists; pharmacists; nurse practitioners; physician assistants; and nurses. Other healthcare professionals involved in the care of patients diagnosed with GI malignancies may benefit from this program.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Analyze expanding clinical applications of radiopharmaceutical therapies in the treatment of neuroendocrine tumors (NETs)
- Describe the first-line treatment options for hepatocellular carcinoma (HCC)
- Describe the role of immunotherapy in the perioperative treatment of patients with MSI-H disease
- Summarize the current guidelines for the diagnosis of early-stage colorectal cancers.
- Describe the role of KRAS targeted therapies in patients with mCRC and other GI malignancies.
- Recognize the latest advancements in surgical techniques for the treatment of pancreatic cancer
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.
Course summary
- 11.25 AAPA Category 1
- 11.25 AMA PRA Category 1 Credit™
- 11.25 ANCC
- 11.25 Attendance
- 11.25 IPCE
Mayo Clinic Gastrointestinal Cancers 2027 | ||
The Ritz-Carlton Ballroom, The Ritz-Carlton, Rancho Mirage, CA | ||
April 2-3, 2027 | ||
Day 1 | Friday, April 2, 2027 | |
6:30 AM | Registration, Breakfast, and Exhibits | |
7:30 AM | Welcome Announcements Tanios S. Bekaii-Saab, M.D. | |
Session I: Pancreas and Neuroendocrine Cancers Moderator: Ben George, M.B.B.S., M.D. | ||
7:40 AM | Radionuclide Therapy in Neuroendocrine Tumors: PRRT Beyond Beta: The Emerging Role of Alpha Emitters Thorvadur R. Halfdanarson, M.D. | |
8:10 AM | RAS Inhibition in Pancreas Cancer: A Seismic Shift in Therapeutic Strategy Tanios S. Bekaii-Saab, M.D. | |
8:40 AM | Beyond RAS Inhibition: Prioritizing Molecular Targets and Trial Strategies in Pancreatic Cancer Michael J. Pishvaian, M.D., Ph.D. | |
9:10 AM | Bringing Precision Therapy Earlier in Pancreatic Cancer: Designing the Right Perioperative Trials John H. Strickler, M.D. | |
9:40 AM | AM Break and Exhibits | |
Session II: Hepatocellular Carcinoma Moderator: Umair Majeed, M.B.B.S., M.D. | ||
10:10 AM | Case Presentations: Can We Get This Patient to Transplant? Cases of HCC Downstaging Presenter: Thomas J. Byrne, M.D. Panel: Kris P. Croome, M.D., Anthony B. El-Khoueiry, M.D., and Rory L. Smoot, M.D. | |
11:00 AM | Intermediate-Stage HCC: Systemic Therapy Alone or in Combination With Locoregional Therapy? Anthony B. El-Khoueiry, M.D. | |
11:30 AM | Resectable HCC: Is It Time to Rethink the Perioperative Paradigm? Rory L. Smoot, M.D. | |
12:00 PM | Lunch and Exhibits | |
12:00 PM | Optional Product Theater: Company 1 (no CME) Location: The Springs Conference Room | |
Session III: Biliary Cancers Moderator: Seyi B. Abidoye, M.B.B.S. | ||
1:00 PM | FGFR2 Fusion–Positive Cholangiocarcinoma: Are We Ready to Move Targeted Therapy to the Front Line? Daniel H. Ahn, D.O. | |
1:20 PM | Perioperative Management of Biliary Tract Cancer: Current Evidence and Future Directions TBC | |
Session IV (part 1): Gastric and Esophageal Cancers Moderator: Jason S. Starr, D.O. | ||
1:40 PM | Organ Preservation in dMMR Gastric/Esophageal Cancer TBC | |
2:10 PM | Spatial Architecture in GI Cancers: Why Does it Matter and How Will It Affect Clinical Care? Kristina A. Matkowskyj, M.D., Ph.D. | |
2:40 PM | Break and Exhibits | |
Session IV (part 2): Gastric and Esophageal Cancers Moderator: Ryan C. Augustin, M.D. | ||
3:10 PM | Targeting HER2 in Esophageal/Gastric Cancer: Beyond Trastuzumab Raghav Sundar, M.D., Ph.D. | |
3:35 PM | Next Generation CLDN18.2 Targeting Florian Lordick, M.D., Ph.D. | |
4:05 PM | Looking Ahead in Gastroesophageal Cancer: Immunotherapy and Emerging Therapies Nataliya V. Uboha, M.D., Ph.D. | |
4:30 PM | Closing Remarks and Adjourn Harry H. Yoon, M.D. | |
|
| |
Day 2 | Saturday, April 3, 2027 | |
6:30 AM | Breakfast and Exhibits | |
6:30 AM | Optional Product Theater: Company 2 (no CME) Location: The Springs Conference Room | |
7:30 AM | Welcome Announcements Tanios S. Bekaii-Saab, M.D. | |
Session V: TBC Moderator: Jeremy C. Jones, M.D. | ||
7:40 AM | Case Presentation: Rectal Cancer: More Options, Harder Decisions. Picking the Right Strategy for the Right Patient Presenter: Conor D. O'Donnell, M.B., B.Ch., B.A.O. Panel: TBC, John H. Strickler, Justin T. Brady, M.D., Toufic Kachaamy, M.D., Eiji Oki B.E., M.E., Ph.D. | |
8:40 AM | Beyond Prognosis: Moving MRD Into Treatment Decision-Making in Colorectal Cancer Takayuki Yoshino, M.D., Ph.D. | |
9:10 AM | Liver Transplantation in CRC: Patient Selection, Timing, and Outcomes Kris P. Croome, M.D. | |
9:40 AM | Break and Exhibits | |
Session VI: Advanced Stage Colorectal Cancers Moderator: Christina S. Wu, M.B., B.Ch., M.D. | ||
10:10 AM | From Molecular Selection to Immune Engagement: Redefining First-Line Therapy in mCRC Christopher H. Lieu, M.D. | |
10:40 AM | Refractory mCRC: How Do We Turn Modest Gains Into Meaningful Benefit? Bassel F. El-Rayes, M.D. | |
11:10 AM | Early-Onset CRC: Defining When Genetics Matters—and When It Does Not Jewel J. Samadder, M.D. | |
11:40 AM | The Next Wave in GI Oncology: New Targets, New Modalities, New Opportunities Kristen K. Ciombor M.D., M.S.C.I. | |
12:10 PM | Closing Remarks and Adjourn TBC | |
There is a limited room block for this course. Once your registration for the course has been completed, please email Merna Shamoun at Shamoun.Merna@mayo.edu to receive the hotel room block link to secure your room. Reservations made using the room block link is strictly reserved for attendees of the course. We reserve the right to cancel your booking without notice if you are not registered for the course.
All travel and lodging expenses are the sole responsibility of the individual registrant.
Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statements:
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA
Mayo Clinic College of Medicine and Science has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 11.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
ANCC
Mayo Clinic College of Medicine and Science designates this activity for a maximum of 11.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
IPCE
This activity was planned by and for the healthcare team, and learners will receive 11.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
| Course / Day | Credit(s) |
|---|---|
| Friday | 6.75 |
| Saturday | 4.50 |
| Total | 11.25 |
Available Credit
- 11.25 AAPA Category 1
- 11.25 AMA PRA Category 1 Credit™
- 11.25 ANCC
- 11.25 Attendance
- 11.25 IPCE
In response to company inquiries, we are excited to share that Gastrointestinal Cancers 2027 course has expanded its commercial support offerings to include a variety of sponsorship opportunities! Please review our 
GICancers2027_Prospectus 1.pdf
If you are interested in exhibiting, please complete the Letter of Agreement.
If you are interested in Sponsoring or hosting a Non-CME Educational Product Theater please email Merna Shamoun for remaining opportunities.
Exhibit space is not confirmed until a representative is notified by a member of the mayo Clinic School of Continuous Professional Development. Exhibitors do not have to register as attendees for the conference. Signed agreements will not be accepted via email.
Please update your profile.
To claim credit for livestream participation in this course, learners must view the content during the hours posted for the live activity. This course is not approved for on-demand delivery.
Commitment to Belonging and Inclusion
Mayo Clinic School of Continuous Professional Development (MCSCPD) strives to foster a learning environment in which all individuals are valued, allowing all to achieve their fullest potential.
Every effort will be made to accommodate dietary requirements; however, some requests may not be feasible based on venue kitchen capabilities. Attendees will be contacted in advance if a dietary restriction cannot be fulfilled.
The Mayo Clinic School of Continuous Professional Development strives for fully accessible learning experiences. If you anticipate any barriers while attending this course, please reach out to the course coordinator who will be in touch with all registrants. If you need disability-related accommodations, please contact the Office of Wellness and Academic Support – Disability Access Services at MCCMS.DS@mayo.edu.
Cancellation and Refund Policy
View Cancellation and Refund Policy
All requests must be submitted in writing using the Contact Us Form.
Any use of this site constitutes your agreement to the Terms and Conditions of Registration.